Transcriptomics

Dataset Information

0

Tumor and gut biopsies from refractory metastatic melanoma patients before and after treatment with fecal microbiota transplantation (FMT) and anti-PD-1 re-induction (Baruch et al, Science 2020)


ABSTRACT: We performed a phase I clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma. FMT donors were two metastatic melanoma patients who achieved a durable complete response. FMT recipient patients were metastatic melanoma patients who failed at least one anti-PD-1 line of treatment. Each recipient patient received FMT implants from only one of the two donors. FMT was conducted by both colonoscopy and oral ingestion of stool capsules, followed by anti-PD-1 re-treatment (Nivolumab, BMS). Recipient patients underwent pre- and post-treatment stool sampling, tissue biopsy of both gut and tumor, and total body imaging. Clinical responses were observed in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE162436 | GEO | 2020/12/31

REPOSITORIES: GEO

Similar Datasets

2023-11-17 | MODEL2310150001 | BioModels
2023-01-13 | GSE221760 | GEO
2022-06-04 | GSE205303 | GEO
| PRJNA695568 | ENA
2019-09-17 | GSE137470 | GEO
2022-08-31 | GSE179670 | GEO
| PRJNA399742 | ENA
| PRJNA307199 | ENA
| phs001493 | dbGaP
2017-12-20 | E-MTAB-6214 | biostudies-arrayexpress